AI assistant
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2024
Jan 9, 2024
32254_dirs_2024-01-09_b4d204d6-bf0d-479e-a702-c932895f0fbb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2024-01-05
Reporting Person: Duker Jay S. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-01-06 | Common Stock | M | 20793.00 | $0.00 | Acquired | 50014.00 | Direct |
| 2024-01-06 | Common Stock | F | 6528.00 | $20.40 | Disposed | 43486.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-01-05 | Restricted Stock Units | $0.00 | A | 90000.00 | Acquired | 2034-01-05 | Common Stock (90000.00) | Direct |
| 2024-01-05 | Stock Option (Right to Buy) | $20.40 | A | 180000.00 | Acquired | 2034-01-04 | Common Stock (180000.00) | Direct |
| 2024-01-06 | Restricted Stock Units | $0.00 | M | 20793.00 | Disposed | 2033-06-19 | Common Stock (20793.00) | Direct |
Footnotes
F1: No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units
F2: The restricted stock units will vest in three ratable annual installments beginning January 5, 2025.
F3: The option to purchase will vest and become exercisable as follows: 25% at January 5th, 2025 and the remainder ratably, on a monthly basis, over the remaining three years.
F4: The restricted stock units vests in three ratable annual installments beginning January 6, 2024.